The recommended dosage of Tenofovir Alafenamide is 25 mg (one tablet) taken orally once daily with or without food.

Elderly patients - Tenofovir Alafenamide dose adjustment is not required in patients aged 65 years and older. In clinical trials, 89 HBV-infected patients aged 65 years and over received TAF 25mg. No differences in safety or efficacy have been observed between elderly patients and those between 18 and less than 65 years of age.

Renal Impairment patients - No dosage adjustment of Tenofovir Alafenamide is required in patients with mild, moderate, or severe renal impairment. Tenofovir Alafenamide is not recommended in patients with end stage renal disease (estimated creatinine clearance below 15 mL per minute). For patients on hemodialysis, on days of hemodialysis, TAF 25mg should be administered after completion of hemodialysis treatment.

Hepatic Impairment patients - No dosage adjustment of Tenofovir Alafenamide is required in patients with mild hepatic impairment (Child-Pugh A). Tenofovir Alafenamide is not recommended in patients with decompensated (Child Pugh B or C) hepatic impairment.

Paediatric population - Safety and effectiveness of Tenofovir Alafenamide in pediatric patients less than 18 years of age havenot been established.

Method of administration

For oral use.

Patients should be instructed to swallow the tablet whole with food

Our other range of products for the treatment of Chronic Hepatitis B includes….

Ricovir:

Molecule: Tenofovir Disoproxil Fumarate 300mg

Gepatit

Molecule: Entecavir 0.5mg